Skip to main content
Top
Published in: Journal of General Internal Medicine 8/2008

01-08-2008 | Original Article

Effects of Increased Patient Cost Sharing on Socioeconomic Disparities in Health Care

Authors: Michael Chernew, PhD, Teresa B. Gibson, PhD, Kristina Yu-Isenberg, PhD, RPh, Michael C. Sokol, MD, MS, Allison B. Rosen, MD, ScD, A. Mark Fendrick, MD

Published in: Journal of General Internal Medicine | Issue 8/2008

Login to get access

Abstract

Background

Increasing patient cost sharing is a commonly employed mechanism to contain health care expenditures.

Objective

To explore whether the impact of increases in prescription drug copayments differs between high- and low-income areas.

Design

Using a database of 6 million enrollees with employer-sponsored health insurance, econometric models were used to examine the relationship between changes in drug copayments and adherence with medications for the treatment of diabetes mellitus (DM) and congestive heart failure (CHF).

Subjects

Individuals 18 years of age and older meeting prespecified diagnostic criteria for DM or CHF were included.

Measurements

Median household income in the patient’s ZIP code of residence from the 2000 Census was used as the measure of income. Adherence was measured by medication possession ratio: the proportion of days on which a patient had a medication available.

Results

Patients in low-income areas were more sensitive to copayment changes than patients in high- or middle-income areas. The relationship between income and price sensitivity was particularly strong for CHF patients. Above the lowest income category, price responsiveness to copayment rates was not consistently related to income.

Conclusions

The relationship between medication adherence and income may account for a portion of the observed disparities in health across socioeconomic groups. Rising copayments may worsen disparities and adversely affect health, particularly among patients living in low-income areas.
Literature
1.
go back to reference National Center for Health Statistics. Health, United States, 1998 with Socioeconomic Status and Health Chartbook. Hyattsville, MD: National Center for Health Statistics; 1998. National Center for Health Statistics. Health, United States, 1998 with Socioeconomic Status and Health Chartbook. Hyattsville, MD: National Center for Health Statistics; 1998.
2.
go back to reference Rao SV, Kaul P, Newby LK, et al. Poverty, process of care, and outcome in acute coronary syndromes. JACC. 2003;41(11):1948–54.PubMed Rao SV, Kaul P, Newby LK, et al. Poverty, process of care, and outcome in acute coronary syndromes. JACC. 2003;41(11):1948–54.PubMed
3.
go back to reference Lemstra M, Neudorf C, Opondo J. Health disparity by neighbourhood income. Can J Public Health. 2006;97(6):435–9.PubMed Lemstra M, Neudorf C, Opondo J. Health disparity by neighbourhood income. Can J Public Health. 2006;97(6):435–9.PubMed
4.
go back to reference Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166(6):737–45.PubMed Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166(6):737–45.PubMed
5.
go back to reference Federman AD, Halm EA, Zhu C, Hochman T, Siu AL. Association of income and prescription drug coverage with generic medication use among older adults with hypertension. Am J Manag Care. 2006;12(10):611–8.PubMed Federman AD, Halm EA, Zhu C, Hochman T, Siu AL. Association of income and prescription drug coverage with generic medication use among older adults with hypertension. Am J Manag Care. 2006;12(10):611–8.PubMed
6.
go back to reference Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27(2):384–91.PubMedCrossRef Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27(2):384–91.PubMedCrossRef
7.
go back to reference Claxton G, Gabel J, Gil I, et al. Health benefits in 2006: premium increases moderate, enrollment in consumer-directed health plans remains modest. Health Aff. 2006;25(6):w476–85.CrossRef Claxton G, Gabel J, Gil I, et al. Health benefits in 2006: premium increases moderate, enrollment in consumer-directed health plans remains modest. Health Aff. 2006;25(6):w476–85.CrossRef
8.
go back to reference Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344–50.PubMedCrossRef Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344–50.PubMedCrossRef
9.
go back to reference Federman AD, Vladeck BC, Siu AL. Avoidance of health care services because of cost: impact of the medicare savings program. Health Aff. 2005;24(1):263–70.CrossRef Federman AD, Vladeck BC, Siu AL. Avoidance of health care services because of cost: impact of the medicare savings program. Health Aff. 2005;24(1):263–70.CrossRef
10.
go back to reference Rice T, Matsuoka KY. The impact of cost-sharing on appropriate utilization and health status: a review of the literature on seniors. Med Care Res Rev. 2004;61(4):415–52.PubMedCrossRef Rice T, Matsuoka KY. The impact of cost-sharing on appropriate utilization and health status: a review of the literature on seniors. Med Care Res Rev. 2004;61(4):415–52.PubMedCrossRef
11.
go back to reference Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61–9.PubMedCrossRef Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61–9.PubMedCrossRef
12.
go back to reference Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166(6):737–45.PubMed Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166(6):737–45.PubMed
13.
go back to reference Pilote L, Beck C, Richard H, Eisenberg MJ. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. CMAJ. 2002;167(3):246–52.PubMed Pilote L, Beck C, Richard H, Eisenberg MJ. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. CMAJ. 2002;167(3):246–52.PubMed
14.
go back to reference Hsu J, Price M, Huang J, et al. Unintended consequences of caps on medicare drug benefits. N Eng J Med. 2006;354(22):2349–59.CrossRef Hsu J, Price M, Huang J, et al. Unintended consequences of caps on medicare drug benefits. N Eng J Med. 2006;354(22):2349–59.CrossRef
15.
go back to reference Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421–9.PubMedCrossRef Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421–9.PubMedCrossRef
16.
go back to reference Bryson CL, Au DH, Young B, McDonell MB, Finh SD. A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care. 2007;45(6):497–504.PubMedCrossRef Bryson CL, Au DH, Young B, McDonell MB, Finh SD. A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care. 2007;45(6):497–504.PubMedCrossRef
17.
go back to reference Gonnella JS, Lewis DZ, Gozum MV, Callahan CA, Barnes CA. Disease Staging: Clinical Criteria, 5th ed. Ann Arbor, MI: Thomson Medstat; 2005. Gonnella JS, Lewis DZ, Gozum MV, Callahan CA, Barnes CA. Disease Staging: Clinical Criteria, 5th ed. Ann Arbor, MI: Thomson Medstat; 2005.
18.
go back to reference Joyce GE, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733–9.PubMedCrossRef Joyce GE, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733–9.PubMedCrossRef
19.
go back to reference Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.PubMedCrossRef Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.PubMedCrossRef
20.
go back to reference Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12(9):509–17.PubMed Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12(9):509–17.PubMed
21.
go back to reference Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy. 2006;26(8):1157–64.PubMedCrossRef Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy. 2006;26(8):1157–64.PubMedCrossRef
22.
go back to reference Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800–5.PubMedCrossRef Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800–5.PubMedCrossRef
23.
go back to reference Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–30.PubMedCrossRef Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–30.PubMedCrossRef
24.
go back to reference Gibson TB, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: the long term and short-term effects on use and expenditures. Inquiry. 2005;42(3):293–310.PubMed Gibson TB, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: the long term and short-term effects on use and expenditures. Inquiry. 2005;42(3):293–310.PubMed
25.
go back to reference Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11):678–83.PubMed Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11):678–83.PubMed
26.
go back to reference Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224–32.PubMedCrossRef Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224–32.PubMedCrossRef
27.
go back to reference Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650–5.PubMedCrossRef Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650–5.PubMedCrossRef
28.
go back to reference Krieger N, Waterman P, Chen JT, Soobader MJ, Subramanian SV, Carson R. Zip code caveat: bias due to spatiotemporal mismatches between ZIP codes and US census-defined geographic areas—the Public Health Disparities Geocoding Project. Am J Pub Health. 2002;92(7):1100–2.PubMedCrossRef Krieger N, Waterman P, Chen JT, Soobader MJ, Subramanian SV, Carson R. Zip code caveat: bias due to spatiotemporal mismatches between ZIP codes and US census-defined geographic areas—the Public Health Disparities Geocoding Project. Am J Pub Health. 2002;92(7):1100–2.PubMedCrossRef
29.
go back to reference Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861–7.PubMed Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861–7.PubMed
30.
go back to reference Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195–203.CrossRef Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195–203.CrossRef
31.
go back to reference Fendrick AM, Chernew ME. Value-based insurance design: a “clinically sensitive, fiscally responsible” approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med. 2007;22(6):890–1.PubMedCrossRef Fendrick AM, Chernew ME. Value-based insurance design: a “clinically sensitive, fiscally responsible” approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med. 2007;22(6):890–1.PubMedCrossRef
32.
go back to reference Freudenheim M. To save later, some employers are offering free drugs now. New York Times. February 21, 2007:A1. Freudenheim M. To save later, some employers are offering free drugs now. New York Times. February 21, 2007:A1.
33.
go back to reference Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in 5 managed care organizations: how much is too much? Med Care. 2005;43(10):951–959.CrossRef Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in 5 managed care organizations: how much is too much? Med Care. 2005;43(10):951–959.CrossRef
Metadata
Title
Effects of Increased Patient Cost Sharing on Socioeconomic Disparities in Health Care
Authors
Michael Chernew, PhD
Teresa B. Gibson, PhD
Kristina Yu-Isenberg, PhD, RPh
Michael C. Sokol, MD, MS
Allison B. Rosen, MD, ScD
A. Mark Fendrick, MD
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 8/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0614-0

Other articles of this Issue 8/2008

Journal of General Internal Medicine 8/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.